Daré Bioscience, Inc. (DARE)
NASDAQ: DARE · Real-Time Price · USD
1.980
-0.040 (-1.98%)
At close: Jun 15, 2026, 4:00 PM EDT
1.982
+0.002 (0.08%)
After-hours: Jun 15, 2026, 7:42 PM EDT
Daré Bioscience Revenue
Daré Bioscience had revenue of $152.46K in the quarter ending March 31, 2026, with 499.58% growth. This brings the company's revenue in the last twelve months to $1.16M, up 4,366.48% year-over-year. In the year 2025, Daré Bioscience had annual revenue of $1.03M with 10,429.33% growth.
Revenue (ttm)
$1.16M
Revenue Growth
+4,366.48%
P/S Ratio
25.63
Revenue / Employee
$48,218
Employees
24
Market Cap
29.66M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.03M | 1.02M | 10,429.33% |
| Dec 31, 2024 | 9.78K | -2.80M | -99.65% |
| Dec 31, 2023 | 2.81M | -7.19M | -71.92% |
| Dec 31, 2022 | 10.00M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | 80.00K | 74.00K | 1,233.33% |
| Dec 31, 2013 | 6.00K | -619.00K | -99.04% |
| Dec 31, 2012 | 625.00K | 619.00K | 10,316.67% |
| Dec 31, 2011 | 6.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Apollomics | 8.84M |
| Evaxion | 7.53M |
| Kyntra Bio | 7.44M |
| Aligos Therapeutics | 4.71M |
| ABVC BioPharma | 797.92K |
| Lisata Therapeutics | 170.00K |
| Actinium Pharmaceuticals | 90.00K |
| INmune Bio | 50.00K |
DARE News
- 4 days ago - Daré Bioscience Transcript: AGM 2026 - Transcripts
- 14 days ago - Daré Bioscience Proxy statement: Proxy filing - Filings
- 14 days ago - Daré Bioscience Proxy statement: Proxy filing - Filings
- 20 days ago - Dare Bioscience receives NIH funding award notice to advance DARE-HPV - TheFly
- 20 days ago - Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer - GlobeNewsWire
- 4 weeks ago - Dare Bioscience initiates DARE-HPV clinical study - TheFly
- 4 weeks ago - Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies - GlobeNewsWire
- 4 weeks ago - Daré Bioscience Earnings Call Transcript: Q1 2026 - Transcripts